Pathophysiology and medical treatment of pain in fibrous dysplasia of bone

Orphanet Journal of Rare Diseases

Volumn 7, Issue SUPPL. 1, 2012, Pages

  Chapurlat, Roland D ^a,b   Gensburger, Deborah ^a,b   Jimenez Andrade, Juan M ^c   Ghilardi, Joseph R ^d   Kelly, Marilyn ^e   Mantyh, Patrick ^c,d,f  

^a UNIVERSITÉ DE LYON   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d VA MEDICAL CENTER   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; DENOSUMAB; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR RECEPTOR; PAMIDRONIC ACID; PROTEIN TYROSINE KINASE A; RISEDRONIC ACID; TOCILIZUMAB; VITAMIN D; ZOLEDRONIC ACID; MONOCLONAL ANTIBODY;

ANALGESIA; BONE DENSITY; BONE GROWTH; BONE PAIN; BONE REMODELING; BONE STRENGTH; CANCER PAIN; CELL SURVIVAL; CONFERENCE PAPER; DISEASE SEVERITY; DRUG SUBSTITUTION; FIBROUS DYSPLASIA; FOLLOW UP; GENE MUTATION; HUMAN; LEG; NERVE CELL DIFFERENTIATION; OSTEOLYSIS; PAIN ASSESSMENT; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSORY NERVE; SPINE; TREATMENT DURATION; TREATMENT FAILURE; BONE; BONE TUMOR; INNERVATION; METHODOLOGY; NERVE FIBER; PAIN; PATHOLOGY; REVIEW; SELF REPORT; SENSORY RECEPTOR;

ALENDRONATE; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE AND BONES; BONE NEOPLASMS; FIBROUS DYSPLASIA OF BONE; HUMANS; NERVE FIBERS; PAIN; PAIN MANAGEMENT; PAIN MEASUREMENT; SELF REPORT; SENSORY RECEPTOR CELLS;

EID: 84861374467     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-7-S1-S3     Document Type: Conference Paper

References (38)

1. Fibrous dysplasia of the bone. Review of twenty-four cases. Firat D, Stutzman L, Am J Med 1968 44 421 429 10.1016/0002-9343(68)90112-5 5644094
2. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Chapurlat RD, Delmas PD, Liens D, Meunier PJ, J Bone Miner Res 1997 12 10 1746 52 10.1359/jbmr.1997.12.10.1746 9333137 (Pubitemid 27422377)
3. Pain in fibrous dysplasia of bone: age-related changes and the anatomical distribution of skeletal lesions. Kelly MH, Brillante B, Collins MT, Osteoporos Int 2008 19 57 63 10.1007/s00198-007-0425-x 17622477 (Pubitemid 350198055)
4. Physical function is impaired but quality of life preserved in patients with fibrous dysplasia of bone. Kelly MH, Brillante B, Kushner H, Gehron Robey P, Collins MT, Bone 2005 37 388 394 10.1016/j.bone.2005.04.026 15963775 (Pubitemid 41160497)
5. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Liens D, Delmas PD, Meunier PJ, Lancet 1994 343 8903 953 4 10.1016/S0140-6736(94)90069-8 7909013 (Pubitemid 24117233)
6. The effect of aging on the density of the sensory nerve fiber innervation of bone and acute skeletal pain. Jimenez-Andrade JM, Mantyh WG, Bloom AP, Freeman KT, Ghilardi JR, Kuskowski MA, Mantyh PW, Neurobiol Aging 2010 33 921 932 20947214
7. A phenotypically restricted set of primary afferent nerve fibers innervate the bone versus skin: Therapeutic opportunity for treating skeletal pain. Jimenez-Andrade JM, Mantyh WG, Bloom AP, Xu H, Ferng AS, Dussor G, Vanderah TW, Mantyh PW, Bone 2011 46 523 529 10.1016/j.bone.2009.09.013 19766746
8. Topographically distinct epidermal nociceptive circuits revealed by axonal tracers targeted to Mrgprd. Zylka MJ, Rice FL, Anderson DJ, Neuron 2005 45 17 25 10.1016/j.neuron.2004.12.015 15629699 (Pubitemid 40075346)
9. Cancer pain and its impact on diagnosis, survival and quality of life. Mantyh PW, Nat Rev Neurosci 2006 7 797 809 16988655 (Pubitemid 44435262)
10. Tanezumab for the treatment of pain from osteoarthritis of the knee. Lane NE, Schnitzer TJ, Birbara CA, Mokhtarani M, Shelton DL, Smith MD, Brown MT, N Engl J Med 2010 363 1521 1531 10.1056/NEJMoa0901510 20942668
11. Blockade of nerve sprouting and neuroma formation markedly attenuates the development of late stage cancer pain. Mantyh WG, Jimenez-Andrade JM, Stake JI, Bloom AP, Kaczmarska MJ, Taylor RN, Freeman KT, Ghilardi JR, Kuskowski MA, Mantyh PW, Neuroscience 2010 171 588 598 10.1016/j.neuroscience.2010.08.056 20851743
12. A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Halvorson KG, Kubota K, Sevcik MA, Lindsay TH, Sotillo JE, Ghilardi JR, Rosol TJ, Boustany L, Shelton DL, Mantyh PW, Cancer Res 2005 65 9426 9435 10.1158/0008-5472.CAN-05-0826 16230406 (Pubitemid 41508011)
13. Pathological sprouting of adult nociceptors in chronic prostate cancer-induced bone pain. Jimenez-Andrade JM, Bloom AP, Stake JI, Mantyh WG, Taylor RN, Freeman KT, Ghilardi JR, Kuskowski MA, Mantyh PW, J Neurosci 2010 30 14649 14656 10.1523/JNEUROSCI.3300-10.2010 21048122
14. Mast cells differentially express and release active high molecular weight neurotrophins. Skaper SD, Pollock M, Facci L, Brain Res Mol Brain Res 2001 97 177 185 11750074 (Pubitemid 34025096)
15. Expression of nerve growth factor and nerve growth factor receptor tyrosine kinase Trk in activated CD4-positive T-cell clones. Ehrhard PB, Erb P, Graumann U, Otten U, Proc Natl Acad Sci USA 1993 90 10984 10988 10.1073/pnas.90.23.10984 7902578 (Pubitemid 23354353)
16. Nerve growth factor expression and innervation of the painful intervertebral disc. Freemont AJ, Watkins A, Le Maitre C, Baird P, Jeziorska M, Knight MT, Ross ER, O'Brien JP, Hoyland JA, J Pathol 2002 197 286 292 10.1002/path.1108 12115873 (Pubitemid 34778297)
17. Increased vascular penetration and nerve growth in the meniscus: a potential source of pain in osteoarthritis. Ashraf S, Wibberley H, Mapp PI, Hill R, Wilson D, Walsh DA, Ann Rheum Dis 2011 70 523 529 10.1136/ard.2010.137844 21081524
18. Neurovascular invasion at the osteochondral junction and in osteophytes in osteoarthritis. Suri S, Gill SE, Massena de Camin S, Wilson D, McWilliams DF, Walsh DA, Ann Rheum Dis 2007 66 1423 1428 10.1136/ard.2006.063354 17446239 (Pubitemid 350032647)
19. Involvement of sensory nerves and immune cells in osteophyte formation in the ankle joint of adjuvant arthritic rats. Wu Z, Nagata K, Iijima T, Histochem Cell Biol 2002 118 213 220 12271357
20. An instrument to measure skeletal burden and predict functional outcome in fibrous dysplasia of bone. Collins MT, Kushner H, Reynolds JC, Chebli C, Kelly MH, Gupta A, et al. J Bone Miner Res 2005 20 2 219 226 15647815
21. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Daut RL, Cleeland CS, Flanery RC, Pain 1983 17 2 197 210 10.1016/0304-3959(83)90143-4 6646795 (Pubitemid 13012221)
22. Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment. Chapurlat RD, Hugueny P, Delmas PD, Meunier PJ, Bone 2004 35 1 235 42 10.1016/j.bone.2004.03.004 15207763 (Pubitemid 38789170)
23. The nonsurgical treatment of fibrous dysplasia. Chapurlat R, Meunier PJ, Rev Rhum Engl Ed 1999 66 1 1 3 10036690 (Pubitemid 29057121)
24. Effect of intravenous pamidronate on bone markers and local bone mineral density in fibrous dysplasia. Parisi MS, Oliveri B, Mautalen CA, Bone 2003 33 4 582 8 10.1016/S8756-3282(03)00221-7 14555262 (Pubitemid 37222384)
25. Long-term aminobisphosphonate treatment of fibrous dysplasia: spectacular increase in bone density. Weinstein RS, J Bone Miner Res 1997 12 8 1314 5 10.1359/jbmr.1997.12.8.1314 9258763 (Pubitemid 27334979)
26. Oral alendronate treatment for polyostotic fibrous dysplasia: a case report. Kitagawa Y, Tamai K, Ito H, J Orthop Sci 2004 9 5 521 5 15449129 (Pubitemid 39410183)
27. Bisphosphonate therapy in fibrous dysplasia. Lane JM, Khan SN, O'Connor WJ, Nydick M, Hommen JP, Schneider R, Tomin E, Brand J, Curtin J, Clin Orthop Relat Res 2001 382 6 12 11154006 (Pubitemid 32047423)
28. Medical therapy in adults with fibrous dysplasia of bone. Chapurlat RD, J Bone Miner Res 2006 21 Suppl 2 114 9 17228999
29. Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone. Plotkin H, Rauch F, Zeitlin L, Munns C, Travers R, Glorieux FH, J Clin Endocrinol Metab 2003 88 10 4569 75 10.1210/jc.2003-030050 14557424 (Pubitemid 37357495)
30. Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome. Lala R, Matarazzo P, Bertelloni S, Buzi F, Rigon F, de Sanctis C, Acta Paediatr 2000 89 2 188 93 10.1111/j.1651-2227.2000.tb01214.x 10709889 (Pubitemid 30339591)
31. Bone turnover in children and adolescents with McCune-Albright syndrome treated with pamidronate for bone fibrous dysplasia. Isaia GC, Lala R, Defilippi C, Matarazzo P, Andreo M, Roggia C, Priolo G, de Sanctis C, Calcif Tissue Int 2002 71 2 121 8 10.1007/s00223-001-1098-7 12200645 (Pubitemid 36935476)
32. Intravenous pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune-Albright syndrome. Zacharin M, OSullivan M, J Pediatr 2000 137 3 403 9 10.1067/mpd.2000.107836 10969268
33. Age-dependent demise of GNAS-mutated skeletal stem cells and normalization of fibrous dysplasia of bone. Kuznetsov SA, Cherman N, Riminucci M, Collins MT, Gehron Robey P, Bianco P, J Bone Miner Res 2008 23 11 1741 40 10.1359/jbmr.080704 18665795
34. http://www.clinicaltrials.gov
35. http://www.dysplasie-fibreuse-des-os.info
36. Increased IL-6 production by cells isolated from the fibrous bone dysplasia tissues in patients with McCune-Albright syndrome. Yamamoto T, Ozono K, Kasayama S, Yoh K, Hiroshima K, Takagi M, Matsumoto S, Michigami T, Yamaoka K, Kishimoto T, Okada S, J Clin Invest 1996 98 30 5 10.1172/JCI118773 8690800 (Pubitemid 26243817)
37. Osteoclastogenesis in fibrous dysplasia of bone: in situ and in vitro analysis of IL-6 expression. Riminucci M, Kuznetsov SA, Cherman N, Corsi A, Bianco P, Gehron Robey P, Bone 2003 33 434 42 10.1016/S8756-3282(03)00064-4 13678786 (Pubitemid 37103260)
38. Rapid and sustained improvement in bone and cartilage markers with the interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate. Garnero P, Mareau E, Thompson E, Woodworth T, Smolen J, Arthritis Rheum 2010 62 33 43 10.1002/art.25053 20039425